# NOTIFICATION OF DEROGATION PURSUANT TO ARTICLE 55(1) OF REGULATION (EU) NO 528/2012

Estonia	
Competent Authority granting the ten	nporary derogation
Organisation	Email address
Health Board	KOOBiotsiid@terviseamet.ee
n case of repeated action: number of	previous action(s)
Product name	
WHO Formulation 2	
Due do et true	
Product type PT 1	
PII	
Active substance(s)	
Propan-2-ol	
Γarget organism(s)	
SARS-CoV-2	
User category	
General public	
Professional user	
Starting date of the action based on A	art. 55 (1) of the BPR
27/03/2020	
End date of the action based on Art.:	55 (1) of the RPR
01/05/2020	
01/03/2020	

• Description of danger the derogation is intended to address

## ☑ danger to public health

As a result of the wide spread of the SARS-CoV-2 coronavirus, disinfectants for hand disinfection are increasingly in demand across Estonia.

The number of confirmed cases of virus SARS-CoV-2 in Estonia is increasing rapidly.

Since the novel coronavirus SARS-CoV-2 is transmitted in a similar way to the flu virus, as a droplet infection, the recommendation to disinfect the hands and surfaces can also be transferred in case of contact with SARS-Cov-2.

Appropriate hand disinfectants are practically no longer available on the market but the need will grow for use in households, public areas, public health facilities and hospitals. There are shortages in supply chain for biocidal products.

In order to secure the supply of hand disinfection products a temporary derogation for the making available on the market and use of the hand disinfectants with the WHO formulation 2 (containing propan-2-ol) have been granted in Estonia.

(describe briefly the danger, the area affected and the effects of the danger)

## $\Box$ danger to environment

(describe briefly the danger, the area affected and the effects of the danger)

#### Geographical area of use

Estonia

Absence of any other means to contain the danger

Due to the urgent demand of the hand disinfectants the procedure according to the art 17 of BPR is too time consuming to get products on the market for the critical period.

#### Limited and controlled use

Manufacturers of biocidal products with the WHO formulation II has to apply for a temporary registration via transitional measure from Health Board.